Who is this relevant for?
- Distributors monitoring sourcing opportunities
Chiesi Farmaceutici has agreed to acquire KalVista Pharmaceuticals for $1.9 billion in cash. The deal, the largest in Chiesi's history, gives the Italian company full control over KalVista's recently approved treatment for hereditary angioedema, a rare genetic condition. The $27 per share offer represents a 40% premium and signals the buyer's commitment to rare immunology.
The acquisition fits Chiesi's stated ambition to reach €6 billion in revenue by 2030. Executives have indicated plans to expand in immune deficiencies, making KalVista's pipeline a natural fit. Financing will come from cash and debt, with completion expected in the third quarter.
For distributors and supply chain operators, the deal opens a channel for a new rare disease therapy with approved U.S. market access. Market watchers will track whether Chiesi leverages its global infrastructure to accelerate commercialization beyond the U.S. The transaction also underscores ongoing consolidation in rare disease pharma, where targeted acquisitions remain a primary growth strategy.